Denmark-based pharmaceutical company Novo Nordisk is to create a research and development centre in Seattle, US, for type 1 diabetes, in order to further research into a disease that the company claims has been neglected.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The centre is due to be opened later this year and will employ 20 researchers, tasked with conducting basic research and early proof-of-concept trials in order provide the necessary foundation to push early-stage discoveries from animal models and into clinical exploratory trials. It will be located on the same site as the company’s inflammation research centre in order to boost synergies between the two fields of research.
Upon announcing the research facility, Novo Nordisk claimed that type 2 diabetes, the more common variant of the disease, has become the main focus for pharmaceutical companies because of the rise of people suffering from the disease in recent times.
Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard said, "It is our mission to take type 1 diabetes research to the next level. With the new type 1 diabetes R&D centre, we hope to accelerate the process of finding new, innovative ways of treating people with this disease."
Of the 366 million people living with diabetes in 2011, it is estimated that just 5-10% of these suffer from the type 1 strain.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCaption: Novo Nordisk’s diabetes research centre in Seattle, US. Image courtesy of: Novo Nordisk.
